Germantown, Maryland-based Senseonics offered its previous-generation continuous glucose monitor (CGM) with a 90-day wear time. Its next-generation Eversense E3 can be used for up to six months (180 days).
Europe already had a 180-day Senseonics CGM system available (Eversense XL), but the next-generation Eversense E3 has a number of improvements on the XL, including reduced calibrations, enhanced survivability and non-adjunctive use, meaning fingersticks aren’t necessary for dosing decisions.
Get the full story at our sister site, Drug Delivery Business News.